期刊文献+

培美曲塞联合顺铂治疗晚期非鳞型非小细胞肺癌的临床观察

Clinical investigation on pemetrexed combined with cisplatin regimen for patients with advanced non-squamous non-small cell lung cancer
原文传递
导出
摘要 目的探讨培美曲塞(PMT)联合顺铂(DDP)治疗晚期非鳞型非小细胞肺癌(NSCLC)的疗效及不良反应。方法收集92例经病理组织学或细胞学确诊的晚期非鳞型NSCLC患者,将其随机分为观察组和对照组,观察组42例,接受PMT联合DDP方案化疗:PMT 500 mg/m2静滴,第1天,联合DDP 25 mg/m2第1-3天。对照组50例,接受多西他赛(DOC)联合DDP方案化疗:DPC 75 mg/m2静滴,第1天,联合DDP 25 mg/m2第1-3天。2组治疗周期均为每3周1次。每例患者均治疗>2个周期,观察2组疗效和不良反应。结果 92例患者完全缓解(CR)5例,部分缓解(PR)34例,稳定(SD)39例,进展(PD)14例。观察组总有效率为52.4%,对照组总有效率为34.0%,2组间比较无统计学差异;观察组主要不良反应包括骨髓抑制、胃肠道反应、脱发等,发生率显著低于对照组(P〈0.05或0.01),且以Ⅰ-Ⅱ级为主。结论 PMT联合DDP方案治疗晚期非鳞型NSCLC疗效与DOC联合DDP方案的疗效相当,但PMT联合DDP的不良反应发生率低,耐受较好。 Objective To investigate the clinical efficacy of pemetrexed combined with cisplatin in the treatment for advanced non-small cell lung cancer. Methods Ninety-two patients with advanced non-squamous NSCLC confirmed with pathology or cytology were enrolled in this study.The patients were divided into observation group and contrast group randomly. Observation group (42 cases) received treatment of pemetrexed( 500 mg/m2 by iv infusion on dl ) combined with isplatin (25 mg/m2 by iv infusion on dl-3). Control group received docetaxel (75 mg/m2 by iv infusion on dl and cisplatin 25 mg/m2 by iv infusion on dl-3). The treatment cycle was once every three weeks. Each patient received at least 2 cycles. The efficacy and side effects were observed. Results The efficacy of the 92 patients were evaluated. Five cases got complete regression (CR) ,34 achieved partial regression (PR) ,39 achieved stable disease (SD) and 14 achieved progressive disease (PD). The effective rate of observation group and control group was 52. 4% and 34. 0% (P〉O. 05). The incidence rate of the main side effects such as myelosuppression, gastrointestinal response and peripheral neurotoxicity in the observa- tion group was significantly higher than that in control group. The side effects were mainly in grade 1-2. Conclusions The clinical efficacy of pemetrexed and docetaxel combined with cisplatin for the treatment of previously untreated advanced NSCLC is roughly the same, but the adverse reactions decrease significantly in the patients receiving the treatment of pemetrexed.
出处 《实用老年医学》 CAS 2014年第5期400-402,共3页 Practical Geriatrics
关键词 非小细胞肺癌 培美曲塞 顺铂 化学治疗 non-small cell lung cancer pemetrexed cisplatin chemotherapy
  • 相关文献

参考文献9

  • 1Al-Saleh K, Quinton C,Ellis PM. Role of pemetrexed in ad-vanced non-small-cell lung cancer: meta-analysis of random-ized controlled trials,with histology subgroup analysis [ J ].Curr Oncol,2012,19( 1) :e9-el5.
  • 2Treat J, Scagliotti GV, Peng G, et al. Comparison ofpemetrexed plus cisplatin with other first-line doublets in ad-vanced non-small cell lung cancer ( nsclc) : a combinedanalysis of three phase 3 trials[ J] . Lung Cancer,2012, 76(2):222-227.
  • 3Ito S, Ogawa Y, Harada H, et al.Long-term survival of pa-tient with brain metastases from lung cancer treated by peme-trexed monotherapy [ J ] . Gan To Kagaku Ryoho, 2012, 39(5);793-796.
  • 4Scagliotti GV, Park K, Patil S, et al. Survival withouttoxicity for cisplatin plus pemetrexed versus cisplatin plusgemcitabine in chemonaive patients with advanced non-smallcell lung cancer: a risk-benefit analysis of a large phase IHstudy [J]. Eur J Cancer ,2009,45( 13) ; 2298-2303.
  • 5Scagliotti GV, Parikh P, von Pawel J, et al.Phase 瓜 studycomparing cisplatin plus gemcitabine with cisplatin pluspemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [ J ]. J Clin Oncol, 2008,26(21);3543-3551.
  • 6Huang MS,Tsai JR,Shen MC,et al.Pemetrexed as a possiblecause of severe rhabdomyolysis in the treatment of lungcancer [ J]. Lung Cancer, 2012,76(3) :491-492.
  • 7Hanna N, Shepherd FA, Fossella FV, et al. Randomizedphase HI trial of pemetrexed versus docetaxel in patients withnon-small-cell lung cancer previously treated with chemo-therapy [J]. J Clin Oncol, 2004,22(9) : 1589-1597.
  • 8Paz-Ares LG, Altug S, Vaury AT, et al.Treatment rationaleand study design for a phase 瓜,double-blind,placebo-con-trolled study of maintenance pemetrexed plus best supportivecare versus best supportive care immediately following induc-tion treatment with pemetrexed plus cisplatin for advancednonsquamous non-small cell lung cancer [ J ]. BMC Cancer,2010,10:85.
  • 9赵富丽,郭人花.培美曲塞加顺铂治疗晚期非小细胞肺癌的效果[J].中国医药导报,2013,10(14):88-90. 被引量:5

二级参考文献12

  • 1王立民,刘信荣,王红阳.非小细胞肺癌的临床治疗进展[J].中国煤炭工业医学杂志,2007,10(1):5-7. 被引量:8
  • 2Dahlberg IJ,Leonardo H,Siannis F,et al. Somatic EGFR mutationand gene copy gain as predictive biomarkers for response to tyrosinekinase inhibitors in non—small cell lung cancer [J]. Clin Cancer Res,2010,16(1):291-303.
  • 3Zinner RG,Fossella FV,Gladish GW,et al. Phase II study of peme-trexed in combination with carboplatin in the firstline treatment ofadvanced nonsmall cell lung cancer [J]. Cancer,2005,104( 11) :2449-2456.
  • 4Scagliotti GV ,Kortsik C, Dark GG,et al. Pemetrexed combined withoxaliplatin or carboplatin as first-line treatment in advanced nons-mall cell lung cancer:a multicenter,randomized,phase II trial [J|.Clin Cancer Res,2005 ,11(2 Pt 1 ):690-696.
  • 5Ettinger DS,Bepler G,Bueno R,et al. Non-small cell lung cancerclinical practice guidelines in oncology [J]. J Natl Compr Cane Netw,2006,4:548-582.
  • 6Rollins KD, Lindley C. Pemetrexed : amultitargted antifolate [J]. ClinTher,2005,27(9):1343.
  • 7Pirker R,Minar W. Chemotherapy of advanced non-small cell lungcancer [J]. Front Radiat The Oncol,2012,42: 157-163.
  • 8Rollins KD, Lindley C. Pemetrexed : amultitargeted antifolate [J]. ClinTher,2004,27(9):1343-1382.
  • 9母连军.培美曲塞获准作为非小细胞肺癌的一线治疗药[J].国外医药(抗生素分册),2008,29(6):285-286. 被引量:26
  • 10吴尉,朱跃红,袁志军,罗以.吉西他滨或培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床比较研究[J].临床和实验医学杂志,2010,9(8):576-577. 被引量:34

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部